Freenome
Freenome to Lay off 20 Percent of Workforce
The cancer early detection firm disclosed the layoffs in a post on LinkedIn, stating that they are necessary to its realignment of strategic priorities.
Investors React to Initial Data on Freenome's Blood-Based Colon Cancer Detection Test
The company's trial results fell short of what some investors had predicted, easing competition concerns for both Guardant Health and Exact Sciences.
Freenome Raises $254M From Roche, Other Investors to Advance Cancer Early Detection Tests
The new funding will allow the firm to further develop its single- and multi-cancer early cancer detection tests that run on its multiomics platform.
Top Five Articles on GenomeWeb Last Week: Invitae, Tome Biosciences, Oncotype Dx Studies, More
Last week, GenomeWeb's readers were most interested in Invitae's divestiture of its Ciitizen Health data platform.
Freenome Launches Prospective Study for Blood-Based Lung Cancer Screening Test
The PROACT LUNG observational trial will recruit up to 20,000 individuals eligible for annual imaging-based screening and will assess the test's performance in comparison.
Jan 11, 2022
Freenome Nets $290M Investment From Roche
Dec 7, 2021
Freenome Raises $300M in Series D Financing
Sep 30, 2021
May 28, 2020
Aug 29, 2019
Jul 24, 2019
Freenome Closes $160M Series B Financing Round
Apr 1, 2019